Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes—or, more accurately, type 1A diabetes—is thought to arise from selective immunologically mediated destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans with consequent insulin deficiency (1). This occurs in individuals in whom genetic susceptibility outweighs genetic protection and is probably initiated by environmental factors not yet clearly defined. The disease arises via a cellular-mediated immune process, presumably a specific reaction to one or more β-cell proteins (autoantigens). There is consequent progressive impairment of β-cell function and apparent decline in β-cell mass. A secondary humoral immune response is characterized by the appearance of autoantibodies that serve as markers of the immune damage to β-cells. This insidious type 1 diabetes disease process generally evolves over a variable period of years (Fig. 1). The decline in β-cell function—and presumably in mass—is evidenced metabolically by loss of first-phase insulin response to an intravenous glucose challenge and later by the appearance of impairment in glycemic regulation, which is manifested as dysglycemia either as impaired glucose tolerance, impaired fasting glucose, or “indeterminate” glucose levels (values >200 mg/dl [11.1 mmol/l] at 30, 60, or 90 min during an oral glucose tolerance test). Ultimately, the clinical syndrome of type 1 diabetes becomes evident when the majority of β-cell function has been lost and presumably most β-cells have been destroyed; at this juncture, frank hyperglycemia supervenes. Although that broad sequence can be articulated, there are still gaps in many of the details. Further understanding of the nature of the disease process will facilitate the design of intervention strategies aimed at abrogating β-cell destruction and ultimately at prophylaxis of type 1 diabetes. FIG. 1. Progression of the type 1 diabetes disease process. This is a cellular autoimmune process occurring in individuals with a genetic predisposition to the disease, presumably triggered by some environmental factor. Humoral antibodies indicate …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vivo reprogramming of adult pancreatic exocrine cells to β-cells
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., & Melton, D. A. (2008) · Nature · doi:10.1038/nature07314 · Cited by 2,010
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“There has been progressive improvement in this field, first with insulin-expressing cells being created, then with insulin-producing cells being developed, and finally with the generation of glucose-responsive insulin-secreting cells (43).”
BackgroundAnti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
Self-citationEffects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520 · cited 3×
“This potential approach involves the use of a number of agents, including 1) an anti-inflammatory agent, such as an anti– interleukin-1 or an anti-tumor necrosis factor, since considerable evidence exists that pancreatic islets are engulfed by an inflammatory response in both type 1 and type 2 diabetes (29); 2) transi…”
BackgroundCouri, C. E. B. (2009) · JAMA · doi:10.1001/jama.2009.470 · Cited by 449
Prediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346 · cited 1×
“To effectively accomplish this requires identification of individuals at risk of type 1 diabetes (14).”
Background(2004) · Controlled Clinical Trials · doi:10.1016/j.cct.2004.08.002 · Cited by 268
Orban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationVendrame, F., Pileggi, A., Laughlin, E., Allende, G., Martin-Pagola, A., Molano, R. D., Diamantopoulos, S., Standifer, N., Geubtner, K., Falk, B. A., et al. (2010) · Diabetes · doi:10.2337/db09-0498 · Cited by 215
Self-citationSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 2×
“This potential approach involves the use of a number of agents, including 1) an anti-inflammatory agent, such as an anti– interleukin-1 or an anti-tumor necrosis factor, since considerable evidence exists that pancreatic islets are engulfed by an inflammatory response in both type 1 and type 2 diabetes (29); 2) transi…”
BackgroundDimorphic histopathology of long-standing childhood-onset diabetes
Gianani, R., Campbell-Thompson, M., Sarkar, S. A., Wasserfall, C., Pugliese, A., Solis, J. M., Kent, S. C., Hering, B. J., West, E., Steck, A., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1642-y · Cited by 158
Sosenko, J. M., Palmer, J. P., Rafkin-Mervis, L., Krischer, J. P., Cuthbertson, D., Mahon, J., Greenbaum, C. J., Cowie, C. C., Skyler, J. S., & the Diabetes Prevention Trial–Type 1 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-2140 · Cited by 76
Self-citationUpdate on Worldwide Efforts to Prevent Type 1 Diabetes
Skyler, J. S., & for the Type 1 Diabetes TrialNet Study Group (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.055 · Cited by 66
Self-citation
Cited by
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60886-6 · Cited by 612
Self-citationMartínez-Pérez, B., de la Torre-Díez, I., & López-Coronado, M. (2013) · Journal of Medical Internet Research · doi:10.2196/jmir.2600 · Cited by 550
“It is estimated that 347 million people have diabetes mellitus [39], commonly named diabetes, but different from diabetes insipidus [40-55].”
BackgroundDiabetes Mellitus in Saudi Arabia: Challenges and Possible Solutions
Al Dawish, M. A., & Robert, A. A. (2020) · Handbook of Healthcare in the Arab World · doi:10.1007/978-3-319-74365-3_45-1 · Cited by 447
Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60895-7 · Cited by 371
Self-citationThe Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314
Metadata
- Authors
- Skyler, J. S., & Ricordi, C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-01
- Volume
- 60
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2151041093
- Cited by
- 109
- References
- 17
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.